ASH 2025 | Patient questionnaire (VRAT) to assess ocular toxicities related to belantamab mafodotin in RRMM

The ProMMise trial is a platform study looking at different combinations of treatments for patients with relapsed multiple myeloma. In cohort D, we are focusing on belantamab mafodotin, which is an antibody drug conjugate targeting BCMA in combination with bortezomib and dexamethasone. Now, we already have the results for this from the DREAMM-7 trial. We know it’s a highly effective treatment and it’s licensed around the world. But the major problem with it is the number of ocular side effects that are associated with the combination, which can be disruptive for patients due to the need for regular ocular assessments. So what we’re investigating in this study, and it’s a live trial that’s currently enrolling in the UK, is whether we can use an alternative method of assessment known as a VRAT or visual-related anatomistic tool, which is essentially a patient questionnaire to take the place of an ocular assessment. So this questionnaire we validated in the DREAMM-2 clinical trial retrospectively and found that we could determine if a patient has a grade three ocular event. And so what we’re doing is that we’re using this now prospectively and patients will be in stage one, have an ocular assessment and a questionnaire. And then in stage two, which we’re about to enter, they’ll be dropping all mandatory ocular assessments and will only be having questionnaires instead. And that will allow us to dose patients according to that. Hopefully early next year we’ll have the initial results which will show whether it’s a safe process to do.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.